Pure Financial Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$350K Buy
561
+38
+7% +$25.9K ﹤0.01% 458
2026
Q1
$404K Buy
523
+26
+5% +$19.9K 0.01% 382
2025
Q4
$384K Buy
497
+130
+35% +$88.3K 0.01% 369
2025
Q3
$207K Buy
+367
New +$208K ﹤0.01% 476

Other funds holding REGN

Pure Financial Advisors's REGN Position: Q2 2026 in Review

Pure Financial Advisors increased its Regeneron Pharmaceuticals (REGN) stake by 7.3% in Q2 2026, buying an estimated $25.9K and bringing the position to 561 shares worth $350K. The position accounts for ﹤0.01% of the portfolio, ranked #458.

Pure Financial Advisors first reported a position in REGN in Q3 2025 and has held it in 4 quarters since. The position peaked at $404K in Q1 2026. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Pure Financial Advisors held 561 shares of Regeneron Pharmaceuticals worth $350K as of Q2 2026.
  • Pure Financial Advisors bought 38 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $25.9K.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Pure Financial Advisors's portfolio in Q2 2026, its #458 holding.
  • Pure Financial Advisors first reported a position in Regeneron Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Pure Financial Advisors's Regeneron Pharmaceuticals position peaked at $404K in Q1 2026.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Pure Financial Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.